BPMX - BioPharmX Corporation

NYSE American - Nasdaq Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5 3.63M
Enterprise Value 3 1.56M
Trailing P/E N/A
Forward P/E 1 -0.32
PEG Ratio (5 yr expected) 1 N/A
Price/Sales (ttm) 93.14
Price/Book (mrq) 2.50
Enterprise Value/Revenue 3 40.05
Enterprise Value/EBITDA 6 -0.10

Trading Information

Stock Price History

Beta (3Y Monthly) 0.01
52-Week Change 3 -90.87%
S&P500 52-Week Change 3 1.73%
52 Week High 3 6.7500
52 Week Low 3 0.3000
50-Day Moving Average 3 0.4187
200-Day Moving Average 3 1.4289

Share Statistics

Avg Vol (3 month) 3 895.76k
Avg Vol (10 day) 3 228.3k
Shares Outstanding 5 N/A
Float 9.75M
% Held by Insiders 1 1.64%
% Held by Institutions 1 18.95%
Shares Short (Jul 31, 2019) 4 231.75k
Short Ratio (Jul 31, 2019) 4 0.34
Short % of Float (Jul 31, 2019) 4 2.37%
Short % of Shares Outstanding (Jul 31, 2019) 4 2.17%
Shares Short (prior month Jun 28, 2019) 4 486.91k

Dividends & Splits

Forward Annual Dividend Rate 4 N/A
Forward Annual Dividend Yield 4 N/A
Trailing Annual Dividend Rate 3 N/A
Trailing Annual Dividend Yield 3 N/A
5 Year Average Dividend Yield 4 N/A
Payout Ratio 4 0.00%
Dividend Date 3 N/A
Ex-Dividend Date 4 N/A
Last Split Factor (new per old) 2 25/1
Last Split Date 3 Apr 26, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Jan 31, 2019
Most Recent Quarter (mrq) Apr 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm) -39,873.08%

Management Effectiveness

Return on Assets (ttm) -118.76%
Return on Equity (ttm) -341.50%

Income Statement

Revenue (ttm) 39k
Revenue Per Share (ttm) 0.00
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) -26k
EBITDA -15.49M
Net Income Avi to Common (ttm) -16.48M
Diluted EPS (ttm) -1.9880
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 3.28M
Total Cash Per Share (mrq) 0.31
Total Debt (mrq) 1.22M
Total Debt/Equity (mrq) 85.39
Current Ratio (mrq) 1.40
Book Value Per Share (mrq) 0.14

Cash Flow Statement

Operating Cash Flow (ttm) -14.72M
Levered Free Cash Flow (ttm) -8.75M